Why invest in KDventures?

KDventures gives investors the opportunity to gain exposure to a portfolio of carefully selected life science companies through a listed share. With specialist expertise, active ownership and a focus on value-driving milestones, we work to create long-term shareholder value.

Exposure to Nordic life science through a listed share

KDventures gives investors the opportunity to gain exposure to a portfolio of life science companies through a single listed share.

We invest in pharmaceutical, biotech and medical technology companies with the potential to address major medical needs and create significant value through clinical development, partnerships, licensing deals and other strategic transactions.

Our portfolio

Through KDventures, shareholders gain exposure to several life science companies and development projects in a single investment.

Specialist expertise

Experience from research, drug development, investments and the capital markets gives us specialist expertise.

Access to private companies

KDventures gives shareholders exposure to both listed and unlisted life science companies.

Risk diversification

A portfolio with several companies and projects provides broader exposure and reduces dependence on a single holding.

A portfolio with value-driving milestones

The value of life science companies can change significantly when important clinical, regulatory or commercial milestones are achieved.

Several of KDventures’ portfolio companies are in development phases where study results, partnerships, licensing deals and other strategic events can become important value drivers.

Through a portfolio with several companies and projects, shareholders gain exposure to multiple potential value drivers over time.

Active ownership with extensive experience

In addition to capital, we contribute experience in strategy, financing, business development, corporate governance and the capital markets. The goal is to help the companies reach the clinical and commercial milestones that can create value for both the portfolio companies and KDventures’ shareholders.

How is the portfolio valued?

A valuation of KDventures’ holdings is carried out each quarter in accordance with international accounting and valuation principles, including IFRS 13 and IPEV.

The portfolio’s fair value corresponds to the assessed value of KDventures’ direct and indirect holdings in the portfolio companies in an orderly transaction between market participants.

Following the acquisition of Rosetta Capital’s shares in KDev Investments during 2026, KDev Investments is a wholly owned subsidiary of KDventures. The previous structure, in which part of future dividends from KDev Investments went to Rosetta Capital, has thereby been eliminated.